Lien Lybaert will take up this role, next to her function at myNEO, to further fulfill Persomed’s goals and boost its growth. Lien has been involved in Persomed since 2019 as operational manager. Last year, she took a more coordinative role and has supervised Persomed on management level as well. Together with #TeamPersomed and partners, Lien is now in contact with multiple corporate investors and risk capital funds and due diligence is ongoing. We aim to close the Series A investment round by the end of Q1 2023.
“I am honoured and excited to be able to contribute to such an ambitious and innovative project. I find the multidisciplinary expertise of Persomed and its partners very inspiring. #Personalized#immunotherapy has a huge potential especially for cancer patients that do not have an intrinsically activated immune system. The Persomed technology has the potential to provide benefit for these patients where the current (immuno)therapies are failing. I am very hopeful for the future and I will do my utmost best to push Persomed further into the next, exciting phase”
